Efficacy and Safety of Dupilumab Maintained in Adults ≥ 60 Years of Age with Moderate-to-Severe Atopic Dermatitis: Analysis of Pooled Data from Four Randomized Clinical Trials

杜皮鲁玛 医学 湿疹面积及严重程度指数 安慰剂 特应性皮炎 不利影响 皮肤科生活质量指数 内科学 随机对照试验 临床试验 皮肤病科 病理 疾病 替代医学
作者
Jonathan I. Silverberg,Charles W Lynde,Katrina Abuabara,Cataldo Patruno,Anna De Benedetto,Haixin Zhang,Ryan B. Thomas,Gaëlle Bégo-Le-Bagousse,Faisal A. Khokhar,Jignesh Vakil,Ainara Rodríguez Marco,Noah A. Levit
出处
期刊:American Journal of Clinical Dermatology [Adis, Springer Healthcare]
卷期号:24 (3): 469-483 被引量:28
标识
DOI:10.1007/s40257-022-00754-4
摘要

BACKGROUND: Adults aged ≥ 60 years are often underrepresented in atopic dermatitis (AD) clinical trials; age-related comorbidities may impact treatment efficacy and safety. OBJECTIVE: The aim was to report dupilumab efficacy and safety in patients aged ≥ 60 years with moderate-to-severe AD. METHODS: Data were pooled from four randomized, placebo-controlled dupilumab trials of patients with moderate-to-severe AD (LIBERTY AD SOLO 1 and 2, LIBERTY AD CAFÉ, and LIBERTY AD CHRONOS) and stratified by age (< 60 [N = 2261] and ≥ 60 [N = 183] years). Patients received dupilumab 300 mg every week (qw) or every 2 weeks (q2w), or placebo with/without topical corticosteroids. Post hoc efficacy at week 16 was examined using broad categorical and continuous assessments of skin lesions, symptoms, biomarkers, and quality of life. Safety was also assessed. RESULTS: In the ≥ 60-year-old group at week 16, a greater proportion of dupilumab-treated patients achieved an Investigator's Global Assessment score of 0/1 (q2w: 44.4%; qw: 39.7%) and 75% improvement in Eczema Area and Severity Index (63.0%; 61.6%) versus placebo (7.1% and 14.3%, respectively; P < 0.0001). Type 2 inflammation biomarkers (immunoglobulin E and thymus and activation-regulated chemokine) were also significantly reduced in dupilumab- versus placebo-treated patients (P < 0.01). Results were similar in the < 60-year-old group. The exposure-adjusted incidences of adverse events in dupilumab-treated patients were generally similar to those receiving placebo, with numerically fewer treatment-emergent adverse events in the dupilumab-treated ≥ 60-year-old group versus placebo. LIMITATIONS: There were fewer patients in the ≥ 60-year-old group; post hoc analyses. CONCLUSION: Dupilumab improved AD signs and symptoms in patients aged ≥ 60 years; results were comparable to those in patients aged < 60 years. Safety was consistent with the known dupilumab safety profile. TRIAL REGISTRATION: ClinicalTrials.gov: NCT02277743, NCT02277769, NCT02755649, NCT02260986. Does dupilumab benefit adults aged 60 years and older with moderate-to-severe atopic dermatitis?(MP4 20,787 KB).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
甲沟炎发布了新的文献求助10
1秒前
北海未暖完成签到,获得积分10
1秒前
1秒前
万能图书馆的应助被知有采纳,获得10
1秒前
阿涛完成签到 ,获得积分10
1秒前
2秒前
轻松忆翠完成签到,获得积分10
3秒前
洞洞幺完成签到 ,获得积分10
3秒前
jack发布了新的文献求助10
3秒前
符聪发布了新的文献求助10
3秒前
3秒前
符聪发布了新的文献求助10
3秒前
符聪发布了新的文献求助10
3秒前
kinlo97完成签到,获得积分10
4秒前
欢呼音响发布了新的文献求助10
4秒前
大模型的应助被搞怪的芙采纳,获得10
4秒前
4秒前
小羊发布了新的文献求助10
5秒前
5秒前
JDK发布了新的文献求助30
5秒前
今后的应助被新楚采纳,获得10
6秒前
6秒前
molihuakai的应助被gsgg采纳,获得10
6秒前
俏皮的沉鱼完成签到,获得积分20
6秒前
6秒前
6秒前
王一发布了新的文献求助10
6秒前
完美世界的应助被King强采纳,获得20
7秒前
7秒前
qolke完成签到,获得积分10
7秒前
HAi完成签到,获得积分10
7秒前
mike发布了新的文献求助10
7秒前
元谷雪的应助被drizzle采纳,获得10
8秒前
Camellia完成签到,获得积分10
10秒前
syh发布了新的文献求助10
10秒前
这样说话完成签到,获得积分10
10秒前
kk完成签到,获得积分10
11秒前
野木生花发布了新的文献求助30
12秒前
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
Resource Recovery Handbook 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8175707
求助须知:如何正确求助?哪些是违规求助? 9567353
关于积分的说明 21792214
捐赠科研通 7770334
什么是DOI,文献DOI怎么找? 3431908
关于科研通互助平台的介绍 2556260
邀请新用户注册赠送积分活动 2477417